By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Biohaven Pharma 

234 Church Street

New Haven  Connecticut  06510  U.S.A.
Phone: n/a Fax: n/a


Key Statistics

Ownership: Public

Web Site: Biohaven
Symbol: BHVN


Company News
Biohaven (BHVN) And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase II Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease 9/15/2017 6:26:55 AM
Biohaven (BHVN) Reports Second Quarter 2017 Financial And Business Results 8/14/2017 7:33:18 AM
Biohaven (BHVN) Completes Randomization In Phase II/III Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017 8/7/2017 7:41:15 AM
Biohaven (BHVN) Appoints Julia P. Gregory To Board Of Directors 8/4/2017 10:59:59 AM
Biohaven (BHVN) Initiates Second Pivotal Phase III Clinical Trial Of Oral CGRP Antagonist For The Acute Treatment Of Migraine 7/31/2017 8:26:59 AM
Biohaven (BHVN) Enrolls First Patient In Pivotal Phase III Clinical Trial Of Oral Rimegepant For The Acute Treatment Of Migraine 7/24/2017 6:21:23 AM
Biohaven (BHVN) Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs 7/13/2017 6:44:18 AM
Biohaven (BHVN)'s BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome 7/6/2017 6:58:03 AM
Biohaven (BHVN) Added to Russell Microcap Index 6/26/2017 7:48:13 AM
Biohaven (BHVN) Broadens Senior Leadership Team With Veteran Pharma Executives 6/22/2017 8:55:21 AM